“When we talk about spine, having 7D, which is a highly differentiable product for deformities, I think it’s giving us the basis to become a real player and help to solve the most complex issues into spine,” Orthofix’s CEO Massimo Calafiore says as he explains the future of spine navigation. In this Vanguards of Health Care episode, Calafiore sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the benefits of its 7D navigation in spine procedures that utilizes camera-based technology combined with machine-vision algorithms, the growth opportunities in specialized orthopedics, including limb preservation and extremity deformity correction, and how he built a new management team from the ground up to tackle these opportunities.

 

&ldquo;When we talk about spine, having 7D, which is a highly differentiable product for deformities, I think it&rsquo;s giving us the basis to become a real player and help to solve the most complex issues into spine,&rdquo; Orthofix&rsquo;s CEO Massimo Calafiore says as he explains the future of spine navigation. In this Vanguards of Health Care episode, Calafiore sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the benefits of its 7D navigation in spine procedures that utilizes camera-based technology combined with machine-vision algorithms, the growth opportunities in specialized orthopedics, including limb preservation and extremity deformity correction, and how he built a new management team from the ground up to tackle these opportunities.
&nbsp;

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Orthofix Builds Specialized Portfolio for the Toughest Ortho and Spine Cases

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ff425436-f39b-4ea0-aa7d-b371010ed545/transcript

“AI agents are at the knee of the curve in terms of where things are headed,” says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis’s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother’s medical journey, fuel his mission to make the system more accessible and equitable.

&ldquo;AI agents are at the knee of the curve in terms of where things are headed,&rdquo; says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis&rsquo;s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother&rsquo;s medical journey, fuel his mission to make the system more accessible and equitable.

Aegis Ventures’ Blueprint for Building AI-Native Companies

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/a3e610d6-87f2-4a01-afc5-b3a900450404/transcript

“In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra level of automation that traditional pumps don't provide,” Beta Bionics CEO Sean Saint explains to Bloomberg Intelligence. In this episode of Vanguards of Health Care, Saint sits down with BI analyst Matt Henriksson for an in-depth interview about Beta’s iLet pump, designed to eliminate the human stress of making insulin dosing decisions. The conversation also touches on the company’s pay as you go strategy through the pharmacy channel and future product development, including the Mint patch pump.

&ldquo;In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra level of automation that traditional pumps don't provide,&rdquo; Beta Bionics CEO Sean Saint explains to Bloomberg Intelligence. In this episode of Vanguards of Health Care, Saint sits down with BI analyst Matt Henriksson for an in-depth interview about Beta&rsquo;s iLet pump, designed to eliminate the human stress of making insulin dosing decisions. The conversation also touches on the company&rsquo;s pay as you go strategy through the pharmacy channel and future product development, including the Mint patch pump.

Beta Bionics Does the Work to Reduce Insulin Pump Burden

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f50ec219-bdc1-4f83-8be6-b39b00fac41a/transcript

Marker 01

Marker 02

Marker 03

Marker 04

Marker 05

Marker 06

Marker 07

Marker 09

Marker 10

Marker 11

“If you’re not going overseas, you’re going out,” says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence’s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun’s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the “Takeda of China.”
Listen to this episode of Vanguards of Health Care on Apple Podcasts and Spotify

&ldquo;If you&rsquo;re not going overseas, you&rsquo;re going out,&rdquo; says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence&rsquo;s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&amp;D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun&rsquo;s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the &ldquo;Takeda of China.&rdquo; Listen to this episode of Vanguards of Health Care on Apple Podcasts and Spotify

Fosun Pharma’s Drive Beyond China

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/5fe8fe3a-5078-49b5-b7aa-b39800f53153/transcript

Orthofix Builds Specialized Portfolio for the Toughest Ortho and Spine Cases

Vanguards of Health Care by Bloomberg Intelligence

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips